Jason P. Holland

TL;DR: It is demonstrated that 89Zr-DFO–labeled mAbs show exceptional promise as radiotracers for immunoPET of human cancers and can be used to delineate and quantify PSMA-positive prostate tumors in vivo.

TL;DR: Small-animal positron emission tomography (PET) imaging studies have demonstrated that free (89)Zr(IV) ions administered as [(89) zirconium-89]Zr-chloride accumulate in the liver, whilst [(89’s) Zr-DFO is excreted rapidly via the kidneys within <20 min, which has important implication for the analysis of immuno-PET imaging of (89), as well as other radiochemistry facilities.

TL;DR: These studies represent the first, to the authors' knowledge, quantitative assessment of CLI for measuring radiotracer uptake in vivo and show excellent promise as a potential new imaging modality for the rapid, high-throughput screening of radiopharmaceuticals.

TL;DR: The question of whether oxygen (or added oxidant) is required to facilitate alkyne dimerization is fully addressed andoretical studies shed more light on the requirement for an oxidant in the homocoupling reaction in order for the process to be theromodynamically favorable.

TL;DR: Target radioimmunotherapy with a SWCNT-([225Ac]DOTA) (E4G10) construct directed at the tumor vasculature in a murine xenograft model of human colon adenocarcinoma and the construct specific activity and blood compartment clearance kinetics were significantly improved relative to corresponding antibodyalone constructs.